Hazem Ghebeh

Dr. Hazem Ghebeh has authored over 50 peer-reviewed original research and review articles and serves as the Principal Investigator on several funded research grants. In addition to his full-time position as a Senior Scientist at KFSHRC, he holds an Assistant Professor appointment at the College of Medicine, Alfaisal University, Riyadh.

Dr. Ghebeh has made significant contributions to understanding the role of PD-L1 expression in cancer biology. He has also contributed to multiple investigator-initiated clinical trials as a principal investigator and co-investigator.

His research focuses on the biology of the immune checkpoint molecule PD-L1 and its role in mediating therapeutic resistance, particularly in aggressive cancer subpopulations such as cancer stem cells (CSCs). His work aims to develop rational combination strategies incorporating anti–PD-L1 therapies to enhance treatment efficacy and overcome cancer therapy resistance.

Immunotherapy of cancer

Cancer stem cells

Prognostic and predictive factors in cancer

Immunohistochemistry of frozen and paraffin-embedded tissues

Flow cytometry (multi-parametric) analysis of labelled calls and sorting cells

Primary cell culture and cell immortalisation

Designing clinical trials and writing protocols

Dr. Ghebeh obtained his Bachelor’s degree in Pharmacy in 1993 and earned his PhD in Microbiology from the University of Manitoba, Winnipeg, Canada, in 2003. He subsequently completed postdoctoral training at Sanofi-Aventis in Toronto, Canada.